CTOs on the Move


 
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.egalet.com
  • 600 Lee Road Suite 100
    Wayne, PA USA 19087
  • Phone: 610.833.4200

Executives

Name Title Contact Details

Similar Companies

Erfa Canada Inc

Erfa Canada Inc is a Westmount, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dassiet

We design and manufacture functional and sustainable applications for human and veterinary immobilization and mobility.

Institute for Therapy through the Arts

The Institute for Therapy through the Arts offers art therapy, music therapy, dance therapy, and drama therapy in Evanston, IL 60201 and Chicagoland.

Blade Therapeutics

Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.

Forma Therapeutics

At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic and metabolic indications.